Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling

Molecular Cancer

Volumn 14, Issue 1, 2015, Pages

  Sandercock, Alan M ^a   Rust, Steven ^a   Guillard, Sandrine ^a   Sachsenmeier, Kris F ^a   Holoweckyj, Nick ^a   Hay, Carl ^a   Flynn, Matt ^a   Huang, Qihui ^a   Yan, Kuan ^b   Herpers, Bram ^b   Price, Leo S ^b   Soden, Jo ^c   Freeth, Jim ^c   Jermutus, Lutz ^a   Hollingsworth, Robert ^a   Minter, Ralph ^a  

^a MEDIMMUNE   (United States)

^b OcellO BV   (Netherlands)

^c Retrogenix   (United Kingdom)

Author keywords

3 D phenotypic screening; Antibody; CDCP1; Cisplatin; DARPin; Multi parametric profiling; Non small cell lung carcinoma; PDX; Phage display

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT; CARBOPLATIN; CDCP1 ANTIBODY; CISPLATIN; CUB DOMAIN CONTAINING PROTEIN 1; DASATINIB; DESIGNED ANKYRIN REPEAT PROTEIN; ENOXAPARIN; ERLOTINIB; FLUTICASONE PROPIONATE PLUS SALMETEROL; GEMCITABINE; MEMBRANE PROTEIN; PACLITAXEL; PEMETREXED; PROTEIN; PROTEIN ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; CDCP1 PROTEIN, HUMAN; CELL ADHESION MOLECULE; LEUKOCYTE ANTIGEN; PEPTIDE LIBRARY; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ANALYSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY ISOLATION; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CANCER MODEL; CANCER STAGING; CASE REPORT; CELL CULTURE; CONTROLLED STUDY; CULTURE TECHNIQUE; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG SCREENING; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IMAGE BASED MULTI PARAMETRIC PROFILING; IN VIVO STUDY; MACHINE LEARNING; MALE; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PHAGE DISPLAY; PHENOTYPE; PHENOTYPIC SCREENING; PRIMARY CELL CULTURE; PRIMARY TUMOR; REPEATED DRUG DOSE; THREE DIMENSIONAL CULTURE; TREATMENT RESPONSE; TUMOR MODEL; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CELL SURFACE DISPLAY; DISEASE MODEL; DRUG DEVELOPMENT; DRUG EFFECTS; IMMUNOLOGY; LUNG TUMOR; METABOLISM; MULTICELLULAR SPHEROID; PEPTIDE LIBRARY; PROCEDURES; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL PRODUCTS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURFACE DISPLAY TECHNIQUES; CISPLATIN; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LUNG NEOPLASMS; MICE; NEOPLASM PROTEINS; PEPTIDE LIBRARY; PHENOTYPE; SINGLE-CHAIN ANTIBODIES; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938059590     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/s12943-015-0415-0     Document Type: Article

References (50)

1. Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov. 2011;10(7):507-19.
2. Rust S, Guillard S, Sachsenmeier K, Hay C, Davidson M, Karlsson A, et al. Combining phenotypic and proteomic approaches to identify membrane targets in a 'triple negative' breast cancer cell type. Mol Cancer. 2013;12:11-4598-12-11.
3. Dudley DT, Li XY, Hu CY, Kleer CG, Willis AL, Weiss SJ. A 3D matrix platform for the rapid generation of therapeutic anti-human carcinoma monoclonal antibodies. Proc Natl Acad Sci U S A. 2014;111(41):14882-7.
4. Kurosawa G, Akahori Y, Morita M, Sumitomo M, Sato N, Muramatsu C, et al. Comprehensive screening for antigens overexpressed on carcinomas via isolation of human mAbs that may be therapeutic. Proc Natl Acad Sci U S A. 2008;105(20):7287-92.
5. Veitonmaki N, Hansson M, Zhan F, Sundberg A, Lofstedt T, Ljungars A, et al. A human ICAM-1 antibody isolated by a function-first approach has potent macrophage-dependent antimyeloma activity in vivo. Cancer Cell. 2013;23(4):502-15.
6. Daniel VC, Marchionni L, Hierman JS, Rhodes JT, Devereux WL, Rudin CM, et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res. 2009;69(8):3364-73.
7. Elliott NT, Yuan F. A review of three-dimensional in vitro tissue models for drug discovery and transport studies. J Pharm Sci. 2011;100(1):59-74.
8. Zhao X, Liu Z, Yu L, Zhang Y, Baxter P, Voicu H, et al. Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma. Neuro Oncol. 2012;14(5):574-83.
9. Loukopoulos P, Kanetaka K, Takamura M, Shibata T, Sakamoto M, Hirohashi S. Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. Pancreas. 2004;29(3):193-203.
10. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med. 2011;17(11):1514-20.
11. Siolas D, Hannon GJ. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res. 2013;73(17):5315-9.
12. Bierwolf J, Lutgehetmann M, Feng K, Erbes J, Deichmann S, Toronyi E, et al. Primary rat hepatocyte culture on 3D nanofibrous polymer scaffolds for toxicology and pharmaceutical research. Biotechnol Bioeng. 2011;108(1):141-50.
13. von der Mark K, Gauss V, von der Mark H, Muller P. Relationship between cell shape and type of collagen synthesised as chondrocytes lose their cartilage phenotype in culture. Nature. 1977;267(5611):531-2.
14. Fennema E, Rivron N, Rouwkema J, van Blitterswijk C, de Boer J. Spheroid culture as a tool for creating 3D complex tissues. Trends Biotechnol. 2013;31(2):108-15.
15. Lin RZ, Chang HY. Recent advances in three-dimensional multicellular spheroid culture for biomedical research. Biotechnol J. 2008;3(9-10):1172-84.
16. Kawasaki H, Yoshida T, Horiguchi K, Ohama T, Sato K. Characterization of anoikis-resistant cells in mouse colonic epithelium. J Vet Med Sci. 2013;75(9):1173-80.
17. Feng Y, Mitchison TJ, Bender A, Young DW, Tallarico JA. Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds. Nat Rev Drug Discov. 2009;8(7):567-78.
18. Neumann B, Walter T, Heriche JK, Bulkescher J, Erfle H, Conrad C, et al. Phenotypic profiling of the human genome by time-lapse microscopy reveals cell division genes. Nature. 2010;464(7289):721-7.
19. Loo LH, Wu LF, Altschuler SJ. Image-based multivariate profiling of drug responses from single cells. Nat Methods. 2007;4(5):445-53.
20. Uekita T, Sakai R. Roles of CUB domain-containing protein 1 signaling in cancer invasion and metastasis. Cancer Sci. 2011;102(11):1943-8.
21. Siva AC, Wild MA, Kirkland RE, Nolan MJ, Lin B, Maruyama T, et al. Targeting CUB domain-containing protein 1 with a monoclonal antibody inhibits metastasis in a prostate cancer model. Cancer Res. 2008;68(10):3759-66.
22. Fukuchi K, Steiniger SC, Deryugina E, Liu Y, Lowery CA, Gloeckner C, et al. Inhibition of tumor metastasis: functional immune modulation of the CUB domain containing protein 1. Mol Pharm. 2010;7(1):245-53.
23. Park JJ, Jin YB, Lee YJ, Lee JS, Lee YS, Ko YG, et al. KAI1 suppresses HIF-1alpha and VEGF expression by blocking CDCP1-enhanced Src activation in prostate cancer. BMC Cancer. 2012;12:81-2407-12-81.
24. Uekita T, Fujii S, Miyazawa Y, Iwakawa R, Narisawa-Saito M, Nakashima K, et al. Oncogenic Ras/ERK signaling activates CDCP1 to promote tumor invasion and metastasis. Mol Cancer Res. 2014;12(10):1449-59.
25. Kollmorgen G, Niederfellner G, Lifke A, Spohn GJ, Rieder N, Vega Harring S, et al. Antibody mediated CDCP1 degradation as mode of action for cancer targeted therapy. Mol Oncol. 2013;7(6):1142-51.
26. Turner L, Lavstsen T, Berger SS, Wang CW, Petersen JE, Avril M, et al. Severe malaria is associated with parasite binding to endothelial protein C receptor. Nature. 2013;498(7455):502-5.
27. Sawada G, Takahashi Y, Niida A, Shimamura T, Kurashige J, Matsumura T, et al. Loss of CDCP1 expression promotes invasiveness and poor prognosis in esophageal squamous cell carcinoma. Ann Surg Oncol. 2014;21(4):640-7.
28. Uekita T, Fujii S, Miyazawa Y, Hashiguchi A, Abe H, Sakamoto M, et al. Suppression of autophagy by CUB domain-containing protein 1 signaling is essential for anchorage-independent survival of lung cancer cells. Cancer Sci. 2013;104(7):865-70.
29. Casar B, Rimann I, Kato H, Shattil SJ, Quigley JP, Deryugina EI. In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated beta1 integrin and induction of FAK/PI3K/Akt motility signaling. Oncogene. 2014;33(2):255-68.
30. Spassov DS, Wong CH, Wong SY, Reiter JF, Moasser MM. Trask loss enhances tumorigenic growth by liberating integrin signaling and growth factor receptor cross-talk in unanchored cells. Cancer Res. 2013;73(3):1168-79.
31. Perry SE, Robinson P, Melcher A, Quirke P, Buhring HJ, Cook GP, et al. Expression of the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cells. FEBS Lett. 2007;581(6):1137-42.
32. Casar B, He Y, Iconomou M, Hooper JD, Quigley JP, Deryugina EI. Blocking of CDCP1 cleavage in vivo prevents Akt-dependent survival and inhibits metastatic colonization through PARP1-mediated apoptosis of cancer cells. Oncogene. 2012;31(35):3924-38.
33. Di Z, Klop MJ, Rogkoti VM, Le Devedec SE, van de Water B, Verbeek FJ, et al. Ultra high content image analysis and phenotype profiling of 3D cultured micro-tissues. PLoS One. 2014;9(10), e109688.
34. Moffat JG, Rudolph J, Bailey D. Phenotypic screening in cancer drug discovery-past, present and future. Nat Rev Drug Discov. 2014;13(8):588-602.
35. Spassov DS, Baehner FL, Wong CH, McDonough S, Moasser MM. The transmembrane src substrate Trask is an epithelial protein that signals during anchorage deprivation. Am J Pathol. 2009;174(5):1756-65.
36. He Y, Wortmann A, Burke LJ, Reid JC, Adams MN, Abdul-Jabbar I, et al. Proteolysis-induced N-terminal ectodomain shedding of the integral membrane glycoprotein CUB domain-containing protein 1 (CDCP1) is accompanied by tyrosine phosphorylation of its C-terminal domain and recruitment of Src and PKCdelta. J Biol Chem. 2010;285(34):26162-73.
37. Spassov DS, Wong CH, Harris G, McDonough S, Phojanakong P, Wang D, et al. A tumor-suppressing function in the epithelial adhesion protein Trask. Oncogene. 2012;31(4):419-31.
38. Lopez-Crapez E, Chypre C, Saavedra J, Marchand J, Grenier J. Rapid and large-scale method to detect K-ras gene mutations in tumor samples. Clin Chem. 1997;43(6):936-42.
39. Yu W, Jin C, Lou X, Han X, Li L, He Y, et al. Global analysis of DNA methylation by methyl-capture sequencing reveals epigenetic control of cisplatin resistance in ovarian cancer cell. PLoS One. 2011;6(12):e29450.
40. Ikeda JI, Morii E, Kimura H, Tomita Y, Takakuwa T, Hasegawa JI, et al. Epigenetic regulation of the expression of the novel stem cell marker CDCP1 in cancer cells. J Pathol. 2006;210(1):75-84.
41. Buhring HJ, Kuci S, Conze T, Rathke G, Bartolovic K, Grunebach F, et al. CDCP1 identifies a broad spectrum of normal and malignant stem/progenitor cell subsets of hematopoietic and nonhematopoietic origin. Stem Cells. 2004;22(3):334-43.
42. Miura S, Hamada S, Masamune A, Satoh K, Shimosegawa T. CUB-domain containing protein 1 represses the epithelial phenotype of pancreatic cancer cells. Exp Cell Res. 2014;321(2):209-18.
43. Lloyd C, Lowe D, Edwards B, Welsh F, Dilks T, Hardman C, et al. Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens. Protein Eng Des Sel. 2009;22(3):159-68.
44. Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, et al. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol. 1996;14(3):309-14.
45. Yan K, Verbeek F. Segmentation for high-throughput image analysis: watershed masked clustering. In: Margaria T, Steffen B, editors. Volume 7610. Berlin Heidelberg: Springer; 2012. p. 25-41.
46. Breiman L. Random forests. Mach Learn. 2001;45(1):5-32.
47. Bezdek JC. Pattern recognition with fuzzy objective function algorithms. Norwell MA, USA: Kluwer Academic Publishers; 1981.
48. Genuer R, Poggi J, Tuleau-Malot C. Variable selection using random forests. Pattern Recog Lett. 2010;31(14):2225.
49. Arbelaitz O, Gurrutxaga I, Muguerza J, Pérez JM, Perona I. An extensive comparative study of cluster validity indices. Pattern Recognit. 2013;46(1):243.
50. Webb AR. Statistical pattern recognition. 2nd ed. Hoboken, NJ: John Wiley & Sons Ltd; 2003.